DJ-X-013 ameliorates inflammation by reducing TNF-α/NF-κB expression and experimental colitis by inducing myeloid-derived suppressor cells

Abstract Inflammation is a body’s defense response for a short duration however if persists for long periods, it causes tissue damage and pathological consequences. Moreover, it paves the way for several diseases including inflammatory bowel disease (IBD). Therefore, there is an urgent need for a natural and safe anti-inflammatory therapeutic compound. To address this issue, we aimed to determine the anti-inflammatory effects of DJ-X-013, using lipopolysaccharide (LPS) activated RAW 264.7 macrophage in vitro and dextran sodium sulfate (DSS) induced experimental model of colitis in vivo. DJ-X-013 drastically reduced tumor necrosis factor-alpha and inducible nitric oxide synthase expression in LPS-activated RAW 264.7 macrophages. Further, DJ-X-013 also impeded the expression of NF-κB and other inflammatory markers and pathways like IL-6, IL-1β, STAT3, ERK, and JNK as compared to LPS-activated cells. Additionally, DJ-X-013 also modulates the migratory activity of RAW 264.7 macrophages during wound healing. Next, using DSS induced colitis model, we observed that the reduction of body weight and colon length were slightly improved in the DJ-X-013 group compared to the control. Intriguingly, myeloid-derived suppressor cells, neutrophils, and CD8 +T cells increased, while Th17 cells frequency decreased in the spleen, mesenteric lymph nodes, and colon lamina propria in DJ-X-013 treated group as compared to DSS. However, natural killer and natural killer T cells were marginally enhanced in the DJ-X-013 group as compared to the DSS alone. Hence, the DJ-X-013 exhibits an immunomodulatory effect and might be a promising drug for IBD and other inflammatory diseases, however, further investigation is required for prudent conclusions. This research is supported by NIH grant R01 AI140405